首页 > 最新文献

Journal of Hypertension最新文献

英文 中文
Response to 'Why the lack of enthusiasm for renal denervation?' 对 "为何对肾脏去神经化缺乏热情?
IF 3.3 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-12-01 Epub Date: 2024-10-31 DOI: 10.1097/HJH.0000000000003867
Andrew S P Sharp, Alice Sanderson, Neil Hansell, Katie Reddish, Paul Miller, Joe Moss, Roland E Schmieder, Rachael McCool
{"title":"Response to 'Why the lack of enthusiasm for renal denervation?'","authors":"Andrew S P Sharp, Alice Sanderson, Neil Hansell, Katie Reddish, Paul Miller, Joe Moss, Roland E Schmieder, Rachael McCool","doi":"10.1097/HJH.0000000000003867","DOIUrl":"10.1097/HJH.0000000000003867","url":null,"abstract":"","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":"42 12","pages":"2215-2217"},"PeriodicalIF":3.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11556867/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142522081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relationship between blood pressure variability and blood pressure phenotypes: a home blood pressure monitoring study. 血压变异性与血压表型之间的关系:家庭血压监测研究。
IF 3.3 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-11-08 DOI: 10.1097/HJH.0000000000003925
Marco A M Alves, Rodrigo Bezerra, Christian S Dal Pont, Marco A Mota-Gomes, Annelise M G Paiva, Weimar S Barroso, Roberto D Miranda, Eduardo C D Barbosa, Andréa A Brandão, José L Lima-Filho, Antonio Coca, Andrei C Sposito, Audes D M Feitosa, Wilson Nadruz

Objective: Home blood pressure (BP) variability (BPV) and BP phenotypes such as white-coat hypertension (WCH), white-coat uncontrolled hypertension (WUCH), masked hypertension (MH) and masked uncontrolled hypertension (MUCH) are predictors of adverse cardiovascular events. This study compared home BPV across BP phenotypes built from abnormal office BP (OBP) and home BP monitoring (HBPM) thresholds defined by three distinct societies [European Society of Hypertension (ESH): OBP ≥ 140/90 mmHg and HBPM ≥ 135/85 mmHg; American College of Cardiology/American Heart Association (ACC/AHA): OBP and HBPM ≥ 130/80 mmHg and Brazilian Society of Cardiology (BSC): OBP ≥ 140/90 mmHg and HBPM ≥ 130/80 mmHg].

Methods: This cross-sectional study evaluated 51 194 treated (37% men, age = 61 ± 15 years) and 56 100 untreated (41% men, age = 54 ± 16 years) individuals from 1045 Brazilian centers who underwent OBP and HBPM measurements. Systolic and diastolic home BPV were estimated as the: standard deviation, coefficient of variation, and the variability independent of the mean of HBPM.

Results: Results of adjusted analysis showed that home BPV parameters were significantly greater in individuals with WCH/WUCH according to the BSC criteria, in those with MH/MUCH defined by the ACC/AHA criteria, and tended to be greater in individuals with either MH/MUCH or WCH/WUCH defined by the ESH criteria.Furthermore, restricted cubic spline analysis showed a U-shaped association between BPV and the difference between OBP and HBPM in treated and untreated individuals.

Conclusion: Home BPV was greater in WCH/WUCH and/or MH/MUCH depending on the criteria used to define abnormal OBP and HBPM thresholds. These findings underscore the need to standardize abnormal BP criteria in clinical practice.

目的:家庭血压(BP)变异性(BPV)和白大衣高血压(WCH)、白大衣失控高血压(WUCH)、掩饰性高血压(MH)和掩饰性失控高血压(MUCH)等血压表型是不良心血管事件的预测因素。本研究比较了由三个不同学会(欧洲高血压学会(ESH)、OBP ≥ 140/90 和 MUCH)定义的异常诊室血压(OBP)和家庭血压监测(HBPM)阈值所建立的不同血压表型的家庭血压值:欧洲高血压学会 (ESH):OBP ≥ 140/90 mmHg 和 HBPM ≥ 135/85 mmHg;美国心脏病学会/美国心脏协会 (ACC/AHA):OBP 和 HBPM ≥ 130/80 mmHg;巴西心脏病学会 (BSC):方法:这项横断面研究评估了来自巴西 1045 个中心的 51 194 名接受治疗者(37% 为男性,年龄 = 61 ± 15 岁)和 56 100 名未接受治疗者(41% 为男性,年龄 = 54 ± 16 岁),他们都接受了 OBP 和 HBPM 测量。收缩压和舒张压家庭血压变异值的估算方法为:标准偏差、变异系数和独立于 HBPM 平均值的变异性:调整后的分析结果显示,根据 BSC 标准,WCH/WUCH 患者的家庭 BPV 参数明显高于根据 ACC/AHA 标准定义的 MH/MUCH 患者,而根据 ESH 标准定义的 MH/MUCH 或 WCH/WUCH 患者的家庭 BPV 参数往往高于根据 ACC/AHA 标准定义的 MH/MUCH 患者:结论:WCH/WUCH 和/或 MH/MUCH 患者的居家 BPV 较高,这取决于用于定义异常 OBP 和 HBPM 临界值的标准。这些发现强调了在临床实践中统一血压异常标准的必要性。
{"title":"Relationship between blood pressure variability and blood pressure phenotypes: a home blood pressure monitoring study.","authors":"Marco A M Alves, Rodrigo Bezerra, Christian S Dal Pont, Marco A Mota-Gomes, Annelise M G Paiva, Weimar S Barroso, Roberto D Miranda, Eduardo C D Barbosa, Andréa A Brandão, José L Lima-Filho, Antonio Coca, Andrei C Sposito, Audes D M Feitosa, Wilson Nadruz","doi":"10.1097/HJH.0000000000003925","DOIUrl":"https://doi.org/10.1097/HJH.0000000000003925","url":null,"abstract":"<p><strong>Objective: </strong>Home blood pressure (BP) variability (BPV) and BP phenotypes such as white-coat hypertension (WCH), white-coat uncontrolled hypertension (WUCH), masked hypertension (MH) and masked uncontrolled hypertension (MUCH) are predictors of adverse cardiovascular events. This study compared home BPV across BP phenotypes built from abnormal office BP (OBP) and home BP monitoring (HBPM) thresholds defined by three distinct societies [European Society of Hypertension (ESH): OBP ≥ 140/90 mmHg and HBPM ≥ 135/85 mmHg; American College of Cardiology/American Heart Association (ACC/AHA): OBP and HBPM ≥ 130/80 mmHg and Brazilian Society of Cardiology (BSC): OBP ≥ 140/90 mmHg and HBPM ≥ 130/80 mmHg].</p><p><strong>Methods: </strong>This cross-sectional study evaluated 51 194 treated (37% men, age = 61 ± 15 years) and 56 100 untreated (41% men, age = 54 ± 16 years) individuals from 1045 Brazilian centers who underwent OBP and HBPM measurements. Systolic and diastolic home BPV were estimated as the: standard deviation, coefficient of variation, and the variability independent of the mean of HBPM.</p><p><strong>Results: </strong>Results of adjusted analysis showed that home BPV parameters were significantly greater in individuals with WCH/WUCH according to the BSC criteria, in those with MH/MUCH defined by the ACC/AHA criteria, and tended to be greater in individuals with either MH/MUCH or WCH/WUCH defined by the ESH criteria.Furthermore, restricted cubic spline analysis showed a U-shaped association between BPV and the difference between OBP and HBPM in treated and untreated individuals.</p><p><strong>Conclusion: </strong>Home BPV was greater in WCH/WUCH and/or MH/MUCH depending on the criteria used to define abnormal OBP and HBPM thresholds. These findings underscore the need to standardize abnormal BP criteria in clinical practice.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142621955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Differences in sex and age response to single pill combination based antihypertensive therapy reflecting in blood pressure and arterial stiffness. 反映血压和动脉僵化的单药联合降压疗法的性别和年龄反应差异。
IF 3.3 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-11-07 DOI: 10.1097/HJH.0000000000003901
Jana Brguljan Hitij, Zbigniew Gaciong, Dragan Simić, Péter Vajer, Parounak Zelveian, Irina E Chazova, Bojan Jelaković

Objective: There are noticeable sex differences in the treatment response to antihypertensives, with limited data on the response to single pill combinations. The aim of the PRECIOUS trial was to assess the treatment response to perindopril/amlodipine and perindopril/amlodipine/indapamide dual and triple single-pill combination in men and women.

Methods: Four hundred and forty adults with essential hypertension were assessed in the 16-week interventional, open-label, prospective, international, multicentre trial. Based on the previous antihypertensive therapy, patients were assigned to either perindopril/amlodipine 4/5 mg or perindopril/amlodipine/indapamide 4/5/1.25 mg, with the initial dose up-titrated in 4-week intervals in case of uncontrolled blood pressure. An additional analysis was performed for sex- and age-related differences on the blood pressure response and arterial stiffness in men and women aged 35-74 years.

Results: Women achieved better overall blood pressure control in all age groups, except for the 35-44 age group. Women presented higher average 24 h aortic augmentation indexes than men, but had more pronounced decreasing trends. The pulse wave velocity was only age-dependent, with reductions slightly greater in women. Both the aortic augmentation index and pulse wave velocity were significantly decreased in all groups compared to baseline.

Conclusions: The results of the PRECIOUS trial contribute significant data to the expanding body of evidence on sex differences in hypertension, including the aspect of age-related changes during the life course of women. The differences between same-aged men and women tend to be smaller with advancing age, but with a greater treatment response in women in all age groups for all observed blood pressure parameters and arterial stiffness.

Trial registration: ClinicalTrials.gov identifier NCT03738761.

目的:降压药的治疗反应存在明显的性别差异,而单药组合的反应数据有限。PRECIOUS 试验旨在评估男性和女性对培哚普利/氨氯地平和培哚普利/氨氯地平/吲达帕胺双联和三联单药组合的治疗反应:在这项为期 16 周的介入性、开放标签、前瞻性、国际多中心试验中,对 440 名成人原发性高血压患者进行了评估。根据之前的降压治疗情况,患者被分配到培哚普利/氨氯地平 4/5 毫克或培哚普利/氨氯地平/吲达帕胺 4/5/1.25 毫克的治疗方案中,如果血压未得到控制,初始剂量每 4 周上调一次。此外,还对 35-74 岁男性和女性在血压反应和动脉僵化方面的性别和年龄差异进行了分析:结果:除 35-44 岁年龄组外,所有年龄组的女性都能更好地控制血压。女性 24 小时平均主动脉增强指数高于男性,但下降趋势更明显。脉搏波速度只与年龄有关,女性的下降幅度略大。与基线相比,所有组别的主动脉增强指数和脉搏波速度都有显著下降:PRECIOUS试验的结果为不断扩大的高血压性别差异证据库提供了重要数据,包括女性生命过程中与年龄相关的变化。随着年龄的增长,同龄男性和女性之间的差异趋于缩小,但在所有观察到的血压参数和动脉僵化方面,所有年龄组的女性都有更大的治疗反应:试验注册:ClinicalTrials.gov 识别码 NCT03738761。
{"title":"Differences in sex and age response to single pill combination based antihypertensive therapy reflecting in blood pressure and arterial stiffness.","authors":"Jana Brguljan Hitij, Zbigniew Gaciong, Dragan Simić, Péter Vajer, Parounak Zelveian, Irina E Chazova, Bojan Jelaković","doi":"10.1097/HJH.0000000000003901","DOIUrl":"10.1097/HJH.0000000000003901","url":null,"abstract":"<p><strong>Objective: </strong>There are noticeable sex differences in the treatment response to antihypertensives, with limited data on the response to single pill combinations. The aim of the PRECIOUS trial was to assess the treatment response to perindopril/amlodipine and perindopril/amlodipine/indapamide dual and triple single-pill combination in men and women.</p><p><strong>Methods: </strong>Four hundred and forty adults with essential hypertension were assessed in the 16-week interventional, open-label, prospective, international, multicentre trial. Based on the previous antihypertensive therapy, patients were assigned to either perindopril/amlodipine 4/5 mg or perindopril/amlodipine/indapamide 4/5/1.25 mg, with the initial dose up-titrated in 4-week intervals in case of uncontrolled blood pressure. An additional analysis was performed for sex- and age-related differences on the blood pressure response and arterial stiffness in men and women aged 35-74 years.</p><p><strong>Results: </strong>Women achieved better overall blood pressure control in all age groups, except for the 35-44 age group. Women presented higher average 24 h aortic augmentation indexes than men, but had more pronounced decreasing trends. The pulse wave velocity was only age-dependent, with reductions slightly greater in women. Both the aortic augmentation index and pulse wave velocity were significantly decreased in all groups compared to baseline.</p><p><strong>Conclusions: </strong>The results of the PRECIOUS trial contribute significant data to the expanding body of evidence on sex differences in hypertension, including the aspect of age-related changes during the life course of women. The differences between same-aged men and women tend to be smaller with advancing age, but with a greater treatment response in women in all age groups for all observed blood pressure parameters and arterial stiffness.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier NCT03738761.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142502043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adherence to antihypertensive medications in Omani patients: a comparison of drug biochemical analysis and the Morisky Medication Adherence Scale. 阿曼患者坚持服用降压药的情况:药物生化分析与莫里斯基坚持服药量表的比较。
IF 3.3 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-11-04 DOI: 10.1097/HJH.0000000000003917
Abdullah Al-Ani, Yousuf Al Suleimani, Sabrina Ritscher, Stefan W Toennes, Amna Al-Hashar, Ibrahim Al-Zakwani, Mohammed Al Za'abi, Khamis Al Hashmi

Background: Medication nonadherence is a major risk factor for suboptimal or failed hypertension pharmacologic therapy.

Objective: To determine the nonadherence rate to antihypertensive medications using high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) and the self-reported Morisky Medication Adherence Scale (MMAS).

Methods: This study used a prospective cross-sectional cohort design. Patients with hypertension aged ≥18 years and prescribed at least one antihypertensive medication were recruited from an outpatient hypertensive clinic at a tertiary healthcare institution in Oman. Adherence was assessed using LC-MS/MS urine analysis and the MMAS.

Results: In total, 162 patients completed the MMAS questionnaire and provided urine samples for LC-MS/MS analysis. The overall mean age of the cohort was 55 ± 13 years, and 57% of the patients were men. The mean systolic and diastolic blood pressures were 146 ± 18 mmHg and 79 ± 10 mmHg, respectively. Using the MMAS method, 65% of the patients reported nonadherence. However, LC-MS/MS analysis revealed that only 27% of the patients were nonadherent. The adherent group by LC-MS/MS had significantly lower systolic (P = 0.026) and diastolic blood pressures (P < 0.001) than the nonadherent group, whereas no differences were observed using the MMAS method. There was weak or no agreement between the MMAS and LC-MS/MS results (P = 0.142).

Conclusion: Almost one-fourth of our patients with hypertension were nonadherent to their medications. There was a weak concordance between the MMAS and LC-MS/MS methods in detecting medication nonadherence. Further research into noninvasive convenient adherence scales or methods and their correlations with LC-MS/MS analysis is warranted.

背景:用药不依从是高血压药物治疗效果不佳或失败的主要风险因素:不坚持用药是高血压药物治疗效果不佳或失败的主要风险因素:使用高效液相色谱-串联质谱法(LC-MS/MS)和自我报告的莫里斯基用药依从性量表(MMAS)确定降压药物的不依从率:本研究采用前瞻性横断面队列设计。研究人员从阿曼一家三级医疗机构的高血压门诊中招募了年龄≥18 岁、至少服用一种降压药的高血压患者。采用 LC-MS/MS 尿液分析和 MMAS 对患者的依从性进行评估:共有 162 名患者填写了 MMAS 问卷,并提供了尿液样本用于 LC-MS/MS 分析。总体平均年龄为 55 ± 13 岁,57% 的患者为男性。平均收缩压和舒张压分别为 146 ± 18 mmHg 和 79 ± 10 mmHg。使用 MMAS 方法,65% 的患者表示没有坚持服药。然而,LC-MS/MS 分析显示,只有 27% 的患者未坚持服药。通过 LC-MS/MS 分析,坚持服药组的收缩压(P = 0.026)和舒张压(P 结论:坚持服药组的收缩压和舒张压均明显低于非坚持服药组:近四分之一的高血压患者没有坚持服药。MMAS 和 LC-MS/MS 方法在检测用药不依从性方面的一致性较弱。有必要进一步研究非侵入性方便的依从性量表或方法及其与 LC-MS/MS 分析的相关性。
{"title":"Adherence to antihypertensive medications in Omani patients: a comparison of drug biochemical analysis and the Morisky Medication Adherence Scale.","authors":"Abdullah Al-Ani, Yousuf Al Suleimani, Sabrina Ritscher, Stefan W Toennes, Amna Al-Hashar, Ibrahim Al-Zakwani, Mohammed Al Za'abi, Khamis Al Hashmi","doi":"10.1097/HJH.0000000000003917","DOIUrl":"https://doi.org/10.1097/HJH.0000000000003917","url":null,"abstract":"<p><strong>Background: </strong>Medication nonadherence is a major risk factor for suboptimal or failed hypertension pharmacologic therapy.</p><p><strong>Objective: </strong>To determine the nonadherence rate to antihypertensive medications using high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) and the self-reported Morisky Medication Adherence Scale (MMAS).</p><p><strong>Methods: </strong>This study used a prospective cross-sectional cohort design. Patients with hypertension aged ≥18 years and prescribed at least one antihypertensive medication were recruited from an outpatient hypertensive clinic at a tertiary healthcare institution in Oman. Adherence was assessed using LC-MS/MS urine analysis and the MMAS.</p><p><strong>Results: </strong>In total, 162 patients completed the MMAS questionnaire and provided urine samples for LC-MS/MS analysis. The overall mean age of the cohort was 55 ± 13 years, and 57% of the patients were men. The mean systolic and diastolic blood pressures were 146 ± 18 mmHg and 79 ± 10 mmHg, respectively. Using the MMAS method, 65% of the patients reported nonadherence. However, LC-MS/MS analysis revealed that only 27% of the patients were nonadherent. The adherent group by LC-MS/MS had significantly lower systolic (P = 0.026) and diastolic blood pressures (P < 0.001) than the nonadherent group, whereas no differences were observed using the MMAS method. There was weak or no agreement between the MMAS and LC-MS/MS results (P = 0.142).</p><p><strong>Conclusion: </strong>Almost one-fourth of our patients with hypertension were nonadherent to their medications. There was a weak concordance between the MMAS and LC-MS/MS methods in detecting medication nonadherence. Further research into noninvasive convenient adherence scales or methods and their correlations with LC-MS/MS analysis is warranted.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142621951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Associations between PM 2.5 and its chemical constituents and blood pressure: a cross-sectional study. PM2.5 及其化学成分与血压之间的关系:一项横断面研究。
IF 3.3 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-11-01 Epub Date: 2024-07-03 DOI: 10.1097/HJH.0000000000003795
Shu Dong, Bin Yu, Chun Yin, Yuchen Li, Wenling Zhong, Chuanteng Feng, Xi Lin, Xu Qiao, Yanrong Yin, Zihang Wang, Tiehui Chen, Hongyun Liu, Peng Jia, Xiaoqing Li, Shujuan Yang

Objectives: To investigate the associations between PM 2.5 and its chemical constituents with blood pressure (BP), assess effects across BP quantiles, and identify the key constituent elevating BP.

Methods: A total of 36 792 adults were included in the cross-sectional study, representing 25 districts/counties of southeast China. Quantile regression models were applied to estimate the associations of PM 2.5 and its chemical constituents (ammonium [NH 4+ ], nitrate [NO 3- ], sulfate [SO 42- ], black carbon [BC], organic matter [OM]) with systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean artery pressure (MAP). A weighted quantile sum (WQS) index was used to estimate the relative importance of each PM 2.5 chemical constituent to the joint effect on BP.

Results: The adverse effects of each interquartile range (IQR) increase in PM 2.5 , NH 4+ , NO 3- , SO 42- , and BC on BP were found to be greater with elevated BP, especially when SBP exceeded 133 mmHg and DBP exceeded 82 mmHg. Each IQR increase in all five PM 2.5 chemical constituents was associated with elevated SBP ( β [95% CI]: 0.90 [0.75, 1.05]), DBP ( β : 0.44 [0.34, 0.53]), and MAP ( β : 0.57 [0.45, 0.69]), NH 4+ (for SBP: weight = 99.43%; for DBP: 12.78%; for MAP: 60.73%) and BC (for DBP: 87.06%; for MAP: 39.07%) predominantly influencing these effects. The joint effect of PM 2.5 chemical constituents on risks for elevated SBP and DBP exhibited an upward trend from the 70 th quantile (SBP exceeded 133 mmHg, DBP exceeded 82 mmHg).

Conclusion: Long-term exposure to PM 2.5 and its chemical constituents was associated with increased risk for elevated BP, with NH 4+ and BC being the main contributors, and such associations were significantly stronger at 70th to 90th quantiles (SBP exceeded 133 mmHg, DBP exceeded 82 mmHg).

目的:研究 PM2.5 及其化学成分与血压之间的关系:调查PM2.5及其化学成分与血压(BP)之间的关系,评估不同血压量级的影响,并确定导致血压升高的关键成分:这项横断面研究共纳入了 36 792 名成年人,他们来自中国东南部的 25 个区/县。应用量值回归模型估计 PM2.5 及其化学成分(铵[NH4+]、硝酸盐[NO3-]、硫酸盐[SO42-]、黑碳[BC]、有机物[OM])与收缩压(SBP)、舒张压(DBP)和平均动脉压(MAP)的关系。采用加权量子和(WQS)指数来估算每种 PM2.5 化学成分对血压联合影响的相对重要性:结果:PM2.5、NH4+、NO3-、SO42- 和 BC 每增加一个四分位数间距(IQR)对血压的不利影响都会随着血压升高而增大,尤其是当 SBP 超过 133 mmHg 和 DBP 超过 82 mmHg 时。所有五种 PM2.5 化学成分每增加一个 IQR 值,SBP(β [95% CI]: 0.90 [0.75, 1.05])、DBP(β: 0.44 [0.34, 0.53])和 MAP(β: 0.57 [0.45, 0.69]),NH4+(对 SBP:权重 = 99.43%;对 DBP:12.78%;对 MAP:60.73%)和 BC(对 DBP:87.06%;对 MAP:39.07%)主要影响这些效应。PM2.5 化学成分对 SBP 和 DBP 升高风险的共同影响从第 70 个量值(SBP 超过 133 mmHg,DBP 超过 82 mmHg)开始呈上升趋势:结论:长期暴露于PM2.5及其化学成分与血压升高的风险增加有关,其中NH4+和BC是主要的致病因素,这种关联在第70至90个量纲(SBP超过133毫米汞柱,DBP超过82毫米汞柱)时明显更强。
{"title":"Associations between PM 2.5 and its chemical constituents and blood pressure: a cross-sectional study.","authors":"Shu Dong, Bin Yu, Chun Yin, Yuchen Li, Wenling Zhong, Chuanteng Feng, Xi Lin, Xu Qiao, Yanrong Yin, Zihang Wang, Tiehui Chen, Hongyun Liu, Peng Jia, Xiaoqing Li, Shujuan Yang","doi":"10.1097/HJH.0000000000003795","DOIUrl":"10.1097/HJH.0000000000003795","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the associations between PM 2.5 and its chemical constituents with blood pressure (BP), assess effects across BP quantiles, and identify the key constituent elevating BP.</p><p><strong>Methods: </strong>A total of 36 792 adults were included in the cross-sectional study, representing 25 districts/counties of southeast China. Quantile regression models were applied to estimate the associations of PM 2.5 and its chemical constituents (ammonium [NH 4+ ], nitrate [NO 3- ], sulfate [SO 42- ], black carbon [BC], organic matter [OM]) with systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean artery pressure (MAP). A weighted quantile sum (WQS) index was used to estimate the relative importance of each PM 2.5 chemical constituent to the joint effect on BP.</p><p><strong>Results: </strong>The adverse effects of each interquartile range (IQR) increase in PM 2.5 , NH 4+ , NO 3- , SO 42- , and BC on BP were found to be greater with elevated BP, especially when SBP exceeded 133 mmHg and DBP exceeded 82 mmHg. Each IQR increase in all five PM 2.5 chemical constituents was associated with elevated SBP ( β [95% CI]: 0.90 [0.75, 1.05]), DBP ( β : 0.44 [0.34, 0.53]), and MAP ( β : 0.57 [0.45, 0.69]), NH 4+ (for SBP: weight = 99.43%; for DBP: 12.78%; for MAP: 60.73%) and BC (for DBP: 87.06%; for MAP: 39.07%) predominantly influencing these effects. The joint effect of PM 2.5 chemical constituents on risks for elevated SBP and DBP exhibited an upward trend from the 70 th quantile (SBP exceeded 133 mmHg, DBP exceeded 82 mmHg).</p><p><strong>Conclusion: </strong>Long-term exposure to PM 2.5 and its chemical constituents was associated with increased risk for elevated BP, with NH 4+ and BC being the main contributors, and such associations were significantly stronger at 70th to 90th quantiles (SBP exceeded 133 mmHg, DBP exceeded 82 mmHg).</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":"1897-1905"},"PeriodicalIF":3.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142154325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Barriers and facilitators to home blood pressure monitoring in women with pregnancies complicated by hypertensive disorders: a qualitative study. 高血压并发症妊娠妇女进行家庭血压监测的障碍和促进因素:一项定性研究。
IF 3.3 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-11-01 Epub Date: 2024-08-09 DOI: 10.1097/HJH.0000000000003835
Lara C Kovell, Mawulorm Denu, Ritika Revoori, Katherine Sadaniantz, Brooke Staples, Germán Chiriboga, Sarah N Forrester, Stephenie C Lemon, Tiffany A Moore Simas, Sharina Person, David D McManus, Kathleen M Mazor

Background/objective: Hypertensive disorders of pregnancy (HDP) are a major cause of maternal morbidity and mortality in the US. Improved diagnosis and treatment of HDP may be achieved through home blood pressure monitoring (HBPM). However, there are challenges to effective HBPM during pregnancy. This qualitative study was conducted to explore patients' perspectives and experiences with HBPM.

Methods: Pregnant or recently postpartum women with HDP (≥18 years) were recruited from an academic medical center to virtual focus groups from March to September 2023. The discussions centered on experiences with HDP and barriers and facilitators to HBPM. Qualitative thematic analysis was performed.

Results: Among 20 participants, the mean age was 33.8 (SD 5.9) years, with 35% Hispanic and 35% Black/African-American. Facilitators to HBPM included understanding the parameters/purpose of HBPM, prior experience with healthcare/duration of hypertension, free access to HBPM equipment and decision support, creating a routine, external support/counseling (e.g., partner/healthcare/family), and technology support. Barriers to HBPM included uncertainty/lack of training about the HBPM process, accessing/using HBPM equipment, the belief that clinic monitoring was sufficient/achieving good control, and activation barriers to making HBPM a priority (e.g., fear of affirming the diagnosis, higher priorities/life stressors).

Conclusion: Many of the barriers to HBPM in pregnancy can be overcome through patient education/counseling, technology support, clinician/family reinforcement, and better access to validated blood pressure monitors. Given the importance of HBPM in improving outcomes for HDP, it is important for healthcare providers and policy makers to work to reduce barriers and amplify facilitators to HBPM for better adoption.

背景/目的:在美国,妊娠高血压疾病(HDP)是导致孕产妇发病和死亡的主要原因。通过家庭血压监测(HBPM)可以改善对 HDP 的诊断和治疗。然而,在孕期进行有效的 HBPM 仍面临挑战。本定性研究旨在探讨患者对 HBPM 的看法和体验:从 2023 年 3 月到 9 月,从一家学术医疗中心招募了患有 HDP 的孕妇或近期产后妇女(≥18 岁)参加虚拟焦点小组。讨论围绕 HDP 经验以及 HBPM 的障碍和促进因素展开。对讨论结果进行了定性专题分析:在 20 位参与者中,平均年龄为 33.8 岁(标准差 5.9),35% 为西班牙裔,35% 为黑人/非裔美国人。促进 HBPM 的因素包括了解 HBPM 的参数/目的、先前的医疗保健经验/高血压持续时间、免费获得 HBPM 设备和决策支持、建立常规、外部支持/咨询(如伴侣/医疗保健/家人)以及技术支持。HBPM 的障碍包括:对 HBPM 过程的不确定性/缺乏培训、获取/使用 HBPM 设备、认为诊所监测就足够了/不能达到很好的控制效果,以及将 HBPM 作为优先事项的激活障碍(如害怕确诊、更优先的事项/生活压力):结论:通过对患者的教育/咨询、技术支持、临床医生/家属的强化以及更好地使用有效的血压计,可以克服妊娠期 HBPM 的许多障碍。鉴于 HBPM 在改善 HDP 治疗效果方面的重要性,医疗保健提供者和政策制定者必须努力减少 HBPM 的障碍并扩大其促进因素,以便更好地采用 HBPM。
{"title":"Barriers and facilitators to home blood pressure monitoring in women with pregnancies complicated by hypertensive disorders: a qualitative study.","authors":"Lara C Kovell, Mawulorm Denu, Ritika Revoori, Katherine Sadaniantz, Brooke Staples, Germán Chiriboga, Sarah N Forrester, Stephenie C Lemon, Tiffany A Moore Simas, Sharina Person, David D McManus, Kathleen M Mazor","doi":"10.1097/HJH.0000000000003835","DOIUrl":"10.1097/HJH.0000000000003835","url":null,"abstract":"<p><strong>Background/objective: </strong>Hypertensive disorders of pregnancy (HDP) are a major cause of maternal morbidity and mortality in the US. Improved diagnosis and treatment of HDP may be achieved through home blood pressure monitoring (HBPM). However, there are challenges to effective HBPM during pregnancy. This qualitative study was conducted to explore patients' perspectives and experiences with HBPM.</p><p><strong>Methods: </strong>Pregnant or recently postpartum women with HDP (≥18 years) were recruited from an academic medical center to virtual focus groups from March to September 2023. The discussions centered on experiences with HDP and barriers and facilitators to HBPM. Qualitative thematic analysis was performed.</p><p><strong>Results: </strong>Among 20 participants, the mean age was 33.8 (SD 5.9) years, with 35% Hispanic and 35% Black/African-American. Facilitators to HBPM included understanding the parameters/purpose of HBPM, prior experience with healthcare/duration of hypertension, free access to HBPM equipment and decision support, creating a routine, external support/counseling (e.g., partner/healthcare/family), and technology support. Barriers to HBPM included uncertainty/lack of training about the HBPM process, accessing/using HBPM equipment, the belief that clinic monitoring was sufficient/achieving good control, and activation barriers to making HBPM a priority (e.g., fear of affirming the diagnosis, higher priorities/life stressors).</p><p><strong>Conclusion: </strong>Many of the barriers to HBPM in pregnancy can be overcome through patient education/counseling, technology support, clinician/family reinforcement, and better access to validated blood pressure monitors. Given the importance of HBPM in improving outcomes for HDP, it is important for healthcare providers and policy makers to work to reduce barriers and amplify facilitators to HBPM for better adoption.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":"1994-2002"},"PeriodicalIF":3.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11449670/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142154327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Formula-led methods using first morning fasting spot urine to assess usual salt intake: a secondary analysis of PURE study data. 使用清晨第一次空腹定点尿液评估通常食盐摄入量的公式主导方法:对 PURE 研究数据的二次分析。
IF 3.3 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-11-01 Epub Date: 2024-08-05 DOI: 10.1097/HJH.0000000000003831
Rachael M McLean, Jing Song, Changqiong Wang, Feng J He, Francesco P Cappuccio, Norm Rc Campbell, Graham A MacGregor

Objectives: Observational studies that assess the relationship between salt intake and long-term outcomes require a valid estimate of usual salt intake. The gold-standard measure in individuals is sodium excretion in multiple nonconsecutive 24-h urines. Multiple studies have demonstrated that random spot urine samples are not valid for estimating usual salt intake; however, some researchers believe that fasting morning spot urine samples produce a better measure of usual salt intake than random spot samples.

Methods: We have used publicly available data from a PURE China validation study to compare estimates of usual salt intake from morning spot urine samples and three published formulae with mean of two 24-h urine samples (reference). We estimated the means and 95% confidence intervals of absolute and relative errors for each formula-led method and the degree to which estimates were able to be classified into the correct quartile of intake. Bland-Altman plots were used to test the level of agreement.

Results: The results show that compared with the reference method, all formulae-led estimates from spot urine collections have high error rates: both random and systematic. This is demonstrated for individual estimates, as well as by quartiles of reference salt intake. This study conclusively demonstrates the unsuitability of morning spot urine formula-led estimates of usual salt intake.

Conclusion: Our findings support international recommendations to not conduct, fund, or publish research studies that use spot urine samples with estimating equations to assess individuals' salt intake in association with health outcomes.

目的:评估盐摄入量与长期结果之间关系的观察性研究需要对通常的盐摄入量进行有效估计。个人的黄金标准测量方法是多次非连续 24 小时尿液中的钠排泄量。多项研究表明,随机定点尿样不能有效估计通常的盐摄入量;但是,一些研究人员认为,与随机定点尿样相比,空腹晨间定点尿样能更好地测量通常的盐摄入量:我们利用纯中国验证研究的公开数据,比较了晨间定点尿样和四种已公布的公式与两个 24 小时尿样的平均值(参考值)对通常盐摄入量的估计值。我们估算了每种以公式为主导的方法的绝对误差和相对误差的平均值和 95% 置信区间,以及能将估算值归入正确的四分位摄入量的程度。我们使用布兰-阿尔特曼图来检验两者的一致程度:结果表明,与参考方法相比,所有以公式为主导的定点尿液采集估计值的误差率都很高:既有随机误差,也有系统误差。这既体现在单个估计值上,也体现在参考盐摄入量的四分位数上。这项研究最终证明,晨间定点尿液公式引导的通常盐摄入量估计值并不合适:我们的研究结果支持国际上提出的建议,即不进行、不资助或不发表使用定点尿样和估计公式来评估个人盐摄入量与健康结果相关性的研究。
{"title":"Formula-led methods using first morning fasting spot urine to assess usual salt intake: a secondary analysis of PURE study data.","authors":"Rachael M McLean, Jing Song, Changqiong Wang, Feng J He, Francesco P Cappuccio, Norm Rc Campbell, Graham A MacGregor","doi":"10.1097/HJH.0000000000003831","DOIUrl":"10.1097/HJH.0000000000003831","url":null,"abstract":"<p><strong>Objectives: </strong>Observational studies that assess the relationship between salt intake and long-term outcomes require a valid estimate of usual salt intake. The gold-standard measure in individuals is sodium excretion in multiple nonconsecutive 24-h urines. Multiple studies have demonstrated that random spot urine samples are not valid for estimating usual salt intake; however, some researchers believe that fasting morning spot urine samples produce a better measure of usual salt intake than random spot samples.</p><p><strong>Methods: </strong>We have used publicly available data from a PURE China validation study to compare estimates of usual salt intake from morning spot urine samples and three published formulae with mean of two 24-h urine samples (reference). We estimated the means and 95% confidence intervals of absolute and relative errors for each formula-led method and the degree to which estimates were able to be classified into the correct quartile of intake. Bland-Altman plots were used to test the level of agreement.</p><p><strong>Results: </strong>The results show that compared with the reference method, all formulae-led estimates from spot urine collections have high error rates: both random and systematic. This is demonstrated for individual estimates, as well as by quartiles of reference salt intake. This study conclusively demonstrates the unsuitability of morning spot urine formula-led estimates of usual salt intake.</p><p><strong>Conclusion: </strong>Our findings support international recommendations to not conduct, fund, or publish research studies that use spot urine samples with estimating equations to assess individuals' salt intake in association with health outcomes.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":"2003-2010"},"PeriodicalIF":3.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142154332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Renal adaptation in pre-obesity patients with hypertension. 肥胖前高血压患者的肾脏适应性。
IF 3.3 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-11-01 Epub Date: 2024-07-19 DOI: 10.1097/HJH.0000000000003821
Agnes Bosch, Manfred Rauh, Kristina Striepe, Mario Schiffer, Roland E Schmieder, Dennis Kannenkeril

Background and hypothesis: Obesity aggravates the risk to develop chronic kidney disease in hypertensive patients. Whether pre-obesity already impairs renal function, renal perfusion and intraglomerular hemodynamics in hypertensive patients is unknown.

Methods: Renal hemodynamic profiles were measured using steady state input clearance (infusion of para-amino-hippuric acid and inulin) in 36 patients with primary arterial hypertension stage 1-2 without antihypertensive medication. Intraglomerular pressure (IGP) and resistances of the afferent (RA) and efferent (RE) arterioles were calculated. The study population was divided into two groups based on median of waist circumference (WC) (96 cm) (pre-obesity and non-obesity group1) and median of body mass index (BMI) (26.5 kg/m 2 ) (pre-obesity and non-obesity group2), respectively.

Results: All patients were males, non-smoking, aged 36 ± 10 years, with an office blood pressure of 145 ± 8.6/89 ± 11.8 mmHg. None of the patients had cardiovascular disease. Patients from the pre-obese group 1 showed lower glomerular filtration rate (GFR), lower renal plasma flow (RPF) and lower IGP compared to the non-obese group1. Renal vascular resistance (RVR) and RA were higher in the pre-obese group1 compared to the non-obese group1. Similar differences in the hemodynamic profile were found for patients in the pre-obesity group2 compared to the non-obesity group2.

Conclusion: The renal hemodynamic profile in hypertensive patients with pre-obesity, irrespective whether defined by WC or BMI, was characterized by a reduced GFR and RPF and by an increased RVR preferentially at the preglomerular site. Our results suggest that hypofiltration is the first phase of renal adaptation in pre-obesity hypertension.

Clinical trial registration: www.clinicaltrials.gov : NCT02783456.

背景和假设:肥胖会增加高血压患者罹患慢性肾病的风险。肥胖前是否已损害高血压患者的肾功能、肾灌注和肾小球内血液动力学尚不清楚:方法:采用稳态输入清除法(输注对氨基硫辛酸和菊粉)测量了 36 名未服用降压药的原发性动脉高血压 1-2 期患者的肾血流动力学状况。计算了肾小球内压(IGP)以及传入动脉(RA)和传出动脉(RE)的阻力。根据腰围(WC)中位数(96 厘米)(肥胖前和非肥胖组1)和体重指数(BMI)中位数(26.5 kg/m2)(肥胖前和非肥胖组2)将研究对象分为两组:所有患者均为男性,不吸烟,年龄(36 ± 10)岁,办公室血压(145 ± 8.6/89 ± 11.8 mmHg)。所有患者均无心血管疾病。与非肥胖组1相比,肥胖前期组1的患者表现出较低的肾小球滤过率(GFR)、较低的肾血浆流量(RPF)和较低的 IGP。与非肥胖组1相比,肥胖前期组1的肾血管阻力(RVR)和RA更高。与非肥胖组2相比,肥胖前期组2患者的血液动力学特征也存在类似差异:结论:肥胖前期高血压患者的肾脏血液动力学特征,不论是以体重指数还是以腹围为标准,都表现为肾小球滤过率和肾小球滤过率降低,肾小球前部的肾小球滤过率增加。我们的研究结果表明,低滤过是肥胖前高血压肾适应的第一阶段。临床试验注册:www.clinicaltrials.gov:NCT02783456。
{"title":"Renal adaptation in pre-obesity patients with hypertension.","authors":"Agnes Bosch, Manfred Rauh, Kristina Striepe, Mario Schiffer, Roland E Schmieder, Dennis Kannenkeril","doi":"10.1097/HJH.0000000000003821","DOIUrl":"10.1097/HJH.0000000000003821","url":null,"abstract":"<p><strong>Background and hypothesis: </strong>Obesity aggravates the risk to develop chronic kidney disease in hypertensive patients. Whether pre-obesity already impairs renal function, renal perfusion and intraglomerular hemodynamics in hypertensive patients is unknown.</p><p><strong>Methods: </strong>Renal hemodynamic profiles were measured using steady state input clearance (infusion of para-amino-hippuric acid and inulin) in 36 patients with primary arterial hypertension stage 1-2 without antihypertensive medication. Intraglomerular pressure (IGP) and resistances of the afferent (RA) and efferent (RE) arterioles were calculated. The study population was divided into two groups based on median of waist circumference (WC) (96 cm) (pre-obesity and non-obesity group1) and median of body mass index (BMI) (26.5 kg/m 2 ) (pre-obesity and non-obesity group2), respectively.</p><p><strong>Results: </strong>All patients were males, non-smoking, aged 36 ± 10 years, with an office blood pressure of 145 ± 8.6/89 ± 11.8 mmHg. None of the patients had cardiovascular disease. Patients from the pre-obese group 1 showed lower glomerular filtration rate (GFR), lower renal plasma flow (RPF) and lower IGP compared to the non-obese group1. Renal vascular resistance (RVR) and RA were higher in the pre-obese group1 compared to the non-obese group1. Similar differences in the hemodynamic profile were found for patients in the pre-obesity group2 compared to the non-obesity group2.</p><p><strong>Conclusion: </strong>The renal hemodynamic profile in hypertensive patients with pre-obesity, irrespective whether defined by WC or BMI, was characterized by a reduced GFR and RPF and by an increased RVR preferentially at the preglomerular site. Our results suggest that hypofiltration is the first phase of renal adaptation in pre-obesity hypertension.</p><p><strong>Clinical trial registration: </strong>www.clinicaltrials.gov : NCT02783456.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":"1958-1965"},"PeriodicalIF":3.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142154339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sustainable hypertension care - a new strategy for an expanding problem. 可持续的高血压护理--解决日益严重问题的新战略。
IF 3.3 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-11-01 Epub Date: 2024-10-03 DOI: 10.1097/HJH.0000000000003842
Peter M Nilsson, Miriam Pikkemaat, Aletta E Schutte
{"title":"Sustainable hypertension care - a new strategy for an expanding problem.","authors":"Peter M Nilsson, Miriam Pikkemaat, Aletta E Schutte","doi":"10.1097/HJH.0000000000003842","DOIUrl":"10.1097/HJH.0000000000003842","url":null,"abstract":"","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":"42 11","pages":"1891-1894"},"PeriodicalIF":3.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Occurrence of hypertension among patients with opioid use disorder in methadone maintenance treatment. 接受美沙酮维持治疗的阿片类药物使用障碍患者中高血压的发生率。
IF 3.3 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-11-01 Epub Date: 2024-10-03 DOI: 10.1097/HJH.0000000000003840
Nirjal Thapa, Don D Shamilov, David F Lo
{"title":"Occurrence of hypertension among patients with opioid use disorder in methadone maintenance treatment.","authors":"Nirjal Thapa, Don D Shamilov, David F Lo","doi":"10.1097/HJH.0000000000003840","DOIUrl":"https://doi.org/10.1097/HJH.0000000000003840","url":null,"abstract":"","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":"42 11","pages":"1895-1896"},"PeriodicalIF":3.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Hypertension
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1